Back to Agenda
Session 2: Approval Pathways and Endpoint Selection
Session Chair(s)
Ashley F. Slagle, PhD, MS
Principal, Scientific and Regulatory Consulting
Aspen Consulting, LLC, United States
Selecting and specifying study endpoints in clinical trials can present challenges to drug developers. Different approval pathways, including traditional approval and expedited pathways, as well as the various types of endpoint approaches that are available can indeed expedite drug development, but can also cause confusion and difficulty in decision-making. The objective of this session is to provide an overview of the approval pathways and endpoint selection considerations. FDA and Industry speakers will share a history, overview of approval pathways, endpoint examples, decision-making considerations, and case studies to help inform future endpoint decisions for drug development programs.
Speaker(s)
Session Co-Chair
Stephen Joel Coons, PhD
Critical Path Institute, United States
Senior Advisor
Overview of Approval Pathways and Implications on Endpoint Selection
Paul Kluetz, MD
FDA, United States
Deputy Director, Oncology Center of Excellence, OC
Endpoints Options and Considerations for Selection
Laura Lee Johnson, PhD
FDA, United States
Director, Division of Biometrics III, Office of Biostatistics, OTS, CDER
Have an account?